Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

€2.7 billion for the treatment of patients with pancreatic cancer: an overview and perspectives in France.

Clinics and research in hepatology and gastroenterology·2026

Same author

Retrospective Analysis of HER2 Testing, Treatment Patterns, and Clinical Outcomes in Patients With Locally Advanced or Metastatic NSCLC With HER2 Mutations in France.

Cancer medicine·2026

Same author

First-Line Sunvozertinib in NSCLC with <i>EGFR</i> Exon 20 Insertion Mutations.

The New England journal of medicine·2026

Same author

Long-Term Response and Survival in Extensive-Stage SCLC Receiving Atezolizumab Plus Chemotherapy in a Real-World Setting: IFCT-1905 CLINATEZO.

JTO clinical and research reports·2026

Same author

PD-1 blockade does not enhance alloimmunization after allogeneic dendritic cell vaccination in cancer patients.

Frontiers in immunology·2026

Same author

Club cell secretory protein (CCSP) serum concentration is a prognostic factor after surgical resection of localized non-small cell lung cancer in patients in the IFCT-0302 trial.

Lung cancer (Amsterdam, Netherlands)·2026

Search research articles

Related Experiment Video

Updated: Oct 18, 2025

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Published on: April 18, 2025

Development and Validation of a Simplified Prognostic Score in SCLC.

Elodie Negre¹, Amandine Coffy², Alexandra Langlais³

¹Department of Thoracic Oncology, Montpellier Regional University Hospital, Montpellier, France.

JTO Clinical and Research Reports

|September 30, 2021

Summary

A new Simplified Prognostic Score (SPS) effectively stratifies small cell lung cancer (SCLC) patients into good, intermediate, and poor survival groups. This score uses TNM stage, performance status, liver metastases, and neutrophil-to-lymphocyte ratio for improved patient stratification.

Keywords:

Chemotherapy Prognosis Prognostic score Serum markers Small cell lung cancer

More Related Videos

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

Related Experiment Videos

Last Updated: Oct 18, 2025

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Published on: April 18, 2025

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

Area of Science:

Oncology
Clinical Prognostics
Biostatistics

Background:

Small cell lung cancer (SCLC) patient outcomes vary significantly.
Accurate prognostic tools are crucial for treatment planning and patient counseling.
Existing prognostic models may lack simplicity or applicability in routine clinical settings.

Purpose of the Study:

To develop and validate a Simplified Prognostic Score (SPS) for patients with SCLC.
To identify key clinical and biological variables that predict overall survival (OS) in SCLC.
To stratify SCLC patients into distinct prognostic subgroups.

Main Methods:

Retrospective analysis of 401 SCLC patients treated with etoposide-platinum chemotherapy.
Development of the SPS using Cox regression model incorporating significant OS determinants.
Validation of the SPS in an independent cohort of 213 patients from published trials.

Main Results:

The SPS incorporates TNM stage IV, ECOG performance status >1, liver metastases, and neutrophil-to-lymphocyte ratio >4.
The score effectively stratified patients into good (26.9 months OS), intermediate (11.5 months OS), and poor (6.8 months OS) prognostic groups.
Validation cohort confirmed similar stratification with median OS of 27.2, 12.3, and 8.6 months, respectively.

Conclusions:

The developed SPS is a simple and effective tool for stratifying SCLC patients into three prognostic categories.
The SPS demonstrates good calibration and discriminative ability in both development and validation cohorts.
Further validation of the SPS in patients receiving immunochemotherapy is warranted.